Enhanced neuropeptide Y immunoreactivity and vasoconstriction in mesenteric small arteries from the early non-obese diabetic mouse

European Journal of Pharmacology

Volumn 539, Issue 3, 2006, Pages 184-191

  Gradin, Kathryn A ^a   Zhu, Hong ^b   Jeansson, Marie ^a   Simonsen, Ulf ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Inst of Anatomy and Cell Biology   (Sweden)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

(Non obese diabetic mice); Acetylcholine; BIBP 3226; Electrical field stimulation; Mesenteric artery; Neuropeptide Y; Noradrenaline

Indexed keywords

GLUCOSE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; PRAZOSIN; TYROSINE 3 MONOOXYGENASE; VASOPRESSIN;

ADRENERGIC TRANSMISSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROSTIMULATION; EVOKED RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HYPERTENSION; IMMUNOREACTIVITY; MESENTERIC ARTERY; MOUSE; MOUSE STRAIN; NERVE CONDUCTION; NERVE ENDING; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SYMPATHETIC NERVE; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROIMMUNOASSAY; MESENTERIC ARTERIES; MICE; MICE, INBRED NOD; NEUROPEPTIDE Y; RECEPTORS, NEUROPEPTIDE Y; TYROSINE 3-MONOOXYGENASE; VASOCONSTRICTION;

EID: 33646856822     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.03.080     Document Type: Article

References (56)

1. Abebe W., and Macleod K.M. Augmented inositol phosphate production in mesenteric arteries from diabetic rats. Eur. J. Pharmacol. 225 (1992) 29-36
2. Adeghate E. Pancreatic tissue grafts are reinnervated by neuro-peptidergic and cholinergic nerves within five days of transplantation. Transpl. Immunol. 10 (2002) 73-80
3. Aguirre J.A., Fuxe K., and Agnati L.F. Increased vasopressor potency of the centrally injected neuropeptide Y fragment 13-36 in the adult spontaneously hypertensive awake male rat of the Wistar-Kyoto strain. Acta Physiol. Scand. 139 (1990) 609-610
4. Akashi T., Nagafuchi S., Anzai K., Kondo S., Kitamura D., Wakana S., Ono J., and Kikuchi M. Direct evidence for the contribution of B cells to the progression of insulitis and the development of diabetes in non-obese mice. Int. Immunol. 9 (1997) 1159-1164
5. Akiyama N., Okumura K., Watanabe Y., Hashimoto H., Ito T., Ogawa K., and Satake T. Altered acetylcholine and norepinephrine concentrations in diabetic rat hearts. Diabetes 38 (1989) 231-236
6. Andersson D., Brunkwall J., Bergquist D., and Edvinsson L. Diminished contractile responses to neuropeptide Y of arteries from diabetic rabbits. J. Auton. Nerv. Syst. 37 (1992) 215-222
7. Andriantsitohaina R., Bian K., Stoclet J.C., and Bukoshi R.D. Neuropeptide Y increases force development through a mechanism that involves calcium entry in resistance arteries. J. Vasc. Res. 30 (1993) 309-314
8. Bauersachs J., Popp R., Hecker M., Sauer E., Fleming I., and Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94 (1996) 3341-3347
9. Bischoff A., and Michel M.C. Neuropeptide Y enhances potasium excretion by mechanism distinct from those controlling sodium excretion. Can. J. Physiol. Pharm. 78 (2000) 93-99
10. Bischoff A., Freund A., and Michel M.L. The Y1 antagonist BIBP 3226 inhibits potentiation of methoxamine-induced vasoconstriction by neuropeptide Y. Naunyn-Schmideberg's Arch. Pharmacol. 356 (1997) 635-640
11. Carlsson P.O., Sandler S., and Jansson L. Pancreatic islet blood perfusion in the nonobese diabetic mouse: diabetic-prone female mice exhibit a higher blood flow compared with male mice in the prediabetic phase. Endocrinology 139 (1998) 3534-3541
12. Cassis L.A., Stitzel R.E., and Head R.J. Hypernoradrenergic innervation of the caudal artery of the spontaneously hypertensive rat: an influence upon neuroeffector mechanisms. J. Pharmacol. Exp. Ther. 234 (1985) 792-803
13. Chavez M., Seeley R.J., Havel P.J., Friedman M.I., Matson C.A., Wood S.E., and Schwartz M.W. Effect of a high-fat diet on food intake and hypothalamic neuropeptide gene expression in streptozocin diabetes. J. Clin. Invest. 102 (1998) 340-346
14. Chow W.L., Zhang L., and MacLeod K.M. Noradrenaline-induced changes in intracellular Ca (2+) and tension in mesenteric arteries from diabetic rats. Br. J. Pharmacol. 134 (2001) 179-187
15. Colwell J.A., Halushka P.V., Sarji K.E., Lopez-Virella M.F., and Sagel J. Vascular disease in diabetes; pathophysiological mechanisms and therapy. Arch. Intern. Med. 139 (1979) 225-230
16. Donohue S.J., Stitzel R.E., and Head R.J. Time course of changes in the norepinephrine content of tissues from spontaneously hypertensive and Wistar Kyoto rats. J. Pharmacol. Exp. Ther. 245 (1988) 24-31
17. Edvinsson L., Jansson I., Cunha e.Sa.M., and Gulbenkian S. Demonstration of neuropeptide containing nerves and vasomotor responses to perivascular peptides in human cerebral arteries. Cephalagia 14 (1994) 88-96
18. Erlinge D., Ekman R., Thulin T., and Edvinsson L. Neuropeptide Y-like immunoreactivity and hypertension. J. Hypertens. 10 (1992) 1221-1225
19. Ganguly P., Bearnish R., Dhalla K., Innes I., and Dhalla N. Norepinephrine storage, distribution and release in diabetic cardiomyopathy. Am. J. Physiol. 252 (1987) E734-E739
20. Garcia M.J., McNamara P.M., Gordon T., and Kanell W.B. Morbidity and mortality in diabetes in the Framingham populations. Sixteen year follow-up study. Diabetes 23 (1974) 104-111
21. Glenn T.C., Krause D.N., and Duckles S.P. Vascular responses to neuropeptide Y are greater in female than male rats. Naunyn Schmiedebergs Arch. Pharmacol. 335 (1997) 111-118
22. Gradin K.A., Li J.Y., Andersson O., and Simonsen U. Enhanced neuropeptide Y immunoreactivity and vasoconstriction in mesenteric arteries from spontaneously hypertensive rats. J. Vasc. Res. 40 (2003) 252-265
23. Hu Y., and Dunbar J.C. Regional vascular and cardiac responses to systemic neuropeptide-Y in normal and diabetic rats. Peptides 18 (1997) 809-815
24. Huggert R.J., Scott E.M., Gilbey S.G., Stoker J.B., Mackintosh A.F., and Mary D.A. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108 (2003) 3097-3101
25. Kawamura K., Ando K., and Takebayashi S. Perivascular innervation of the mesenteric artery in spontaneously hypertensive rats. Hypertension 14 (1989) 660-665
26. Koulu M., Movafagh S., Tuohimaa J., Jaakkola U., Kallio J., Pesonen U., Geng Y., Karvonen M.K., Vaino-Jylha E., Pollonen M., Kaipio-Salmi K., Seppala H., Lee E.W., Higgins R.D., and Zukowska Z. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann. Med. 36 (2004) 232-240
27. Kuncova J., Sviglerova J., Tonar Z., and Slavikova J. Heterogenous changes in neuropeptide Y, norepinephrine and epinephrine concentrations in the hearts of diabetic rats. Auton. Neurosci. 121 (2005) 7-15
28. Levy D.M., Karanth S.S., Springall D.K., and Polak J.M. Depletion of cutaneous nerves and neuropeptides in diabetes mellitus: an immunocytochemical study. Diabetologia 32 (1989) 427-433
29. Lind H., Erlinge D., Brunkwall J., and Edvinsson L. Selective attenuation of neuropeptide-Y-mediated contractile responses in blood vessels from patients with diabetes mellitus. Clin. Auton. Res. 5 (1995) 191-197
30. Longhurst P.A., and Head R.J. Responses of the isolated perfused mesenteric vasculature from diabetic rats: the significance of appropriate control tissues. J. Pharmacol. Exp. Ther. 235 (1985) 45-49
31. Macleod K.M. The effect of insulin treatment on changes in vascular reactivity in chronic, experimental diabetes. Diabetes 34 (1985) 1160-1167
32. Mc Nally P.G., Watt P.A., Rimner T., Burdui A.C., Hearnshaw J.R., and Thurston H. Impaired contraction and endothelium-dependent relaxation in isolated resistance vessels from patients with insulin-dependent diabetic mellitus. Clin. Sci. 87 (1994) 31-36
33. Mezzano V., Donoso V., Capurro D., and Huidobro-Toro J.P. Increased neuropeptide Y pressor activity in Goldblatt hypertension rats: in vivo studies with BIBP 3226. Peptides 19 (1998) 1227-1232
34. Michel M.C., Beck-Sickinger A., and Cox H. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50 (1998) 143-150
35. Milewicz A., Mikulski E., and Bidzinska B. Plasma insulin, cholecystokinin, galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 24 (2000) S152-S153
36. Mueed I., Zhang L., and Mac Leod K.M. Role of the PKC/CPI-17 pathway in enhanced contractile responses of mesenteric arteries from diabetic rats to alpha-adrenoceptor stimulation. Br. J. Pharmacol. 146 (2005) 972-982
37. Prieto D., Buus C.L., Mulvany M.J., and Nilsson H. Neuropeptide Y regulates intracellular calcium through different signalling pathways linked to a Y(1)-receptor in rat mesenteric small arteries. Br. J. Pharmacol. 129 (2000) 1689-1699
38. Ralevic V., Belai A., and Burnstock G. Effects of streptozotocin-diabetes on sympathetic nerve, endothelial and smooth muscle function in the rat mesenteric arterial bed. Eur. J. Pharmacol. 286 (1995) 193-199
39. Sasaki S., and Bunag R.D. Hypothalamic responsiveness in DOCA hypertensive rats augmented by streptozotocin-induced diabetes. J. Cardiovasc. Pharmacol. 4 (1982) 1042-1048
40. Satoh C., Satoh F., Takahashi K., Murakami O., Sone M., Totsune K., Yabe T., Ohneda M., Fakuda M., Sugimura K., Ogawa S., Nagakubo H., Sato T., and Mouri T. Elevated plasma neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy. Endocr. J. 46 (1999) 139-146
41. Savage M.W., Bodmer C.W., Walker A.B., Buchan I.E., Masson E.A., and Williams G. Vascular reactivity to noradrenaline and neuropeptide Y in the streptozotocin-induced diabetic rat. Eur. J. Clin. Invest. 25 (1995) 974-979
42. Schmidt R.E., Dorsey D.A., Beaudet L.N., Frederick K.E., Parvin C.A., Plurad S.B., and Levisetti M.G. Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy: a new experimental model of diabetic autonomic neuropathy. Am. J. Pathol. 163 (2003) 2077-2091
43. Scott T.M., and Pang S.C. The correlation between the development of sympathetic innervation and the development of medial hypertrophy in jejunal arteries in normotensive and spontaneously hypertensive rats. J. Auton. Nerv. Syst. 8 (1983) 25-32
44. Setty S., Sun W., Martinez R., Downey H.F., and Tune J.D. Alpha-adrenoceptor-mediated coronary vasoconstriction is augmented during exercise in experimental diabetes mellitus. J. Appl. Physiol. 97 (2004) 431-438
45. Sjogren A., and Edvinsson L. The influence of magnesium on the release of calcium from intracellular depots in vascular smooth muscle cells. Pharmacol. Toxicol. 62 (1988) 17-21
46. Spangeus A., Forsgren S., and El-Salhy M. Does the diabetic state affect co-localization of peptide YY and enteroglucagon in colonic endocrine cells?. Histol. Histopathol. 15 (2000) 37-41
47. Sundkvist G., Bramnert M., Bergstrom B., Manhem P., Lilja B., and Ahren B. Plasma neuropeptide Y (NPY) and galanin before and during exercise in type 1 diabetic patients with autonomic dysfunction. Diabetes Res. Clin. Pract. 15 (1992) 219-226
48. Takiguchi Y., Satoh N., Hashimoto H., and Nakashima M. Changes in vascular reactivity in experimental diabetic rats: comparison with hyperthyroid rats. Blood Vessels 25 (1988) 250-260
49. Taylor P.D., McCarthy A.L., Thomas C.R., and Poston L. Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric arteries of streptozotocin-induced diabetic rats. Br. J. Pharmacol. 107 (1992) 393-399
50. Taylor P.D., Don B.B., Thomas C.R., and Poston L. Prevention by insulin treatment of endothelial dysfunction but not enhanced noradrenaline induced contractility in mesenteric resistance arteries from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 111 (1994) 35-41
51. Torffvit O., and Edvinsson L. Blockade of nitric oxide decreases the renal vasodilatory effect of neuropeptide Y in the insulin-treated rat. Pflugers Arch. 434 (1997) 445-450
52. White R.E., and Carrier G.O. Vascular contraction induced by activation of membrane calcium ion channels is enhanced in streptozotocin-diabetes. J. Pharmacol. Exp. Ther. 253 (1990) 1057-1062
53. White J.D., Olchovsky D., Kershawi M., and Berelowitz M. Increased hypothalamic content of preproneuropeptide-Y messenger ribonucleic acid in streptozotocin-diabetic rats. Endocrinology 126 (1990) 765-772
54. Wocial B., Ignatowska-Switalska H., Pruszczyk P., Jedrusik P., Januszewicz A., Lapinski M., Januszewicz W., and Zukowska-Grojec Z. Plasma neuropeptide Y and catecholamines in woman and men with essential hypertension. Blood Pressure 4 (1995) 143-147
55. You J., Edvinsson L., and Bryan R.U. Neuropeptide Y-mediated constriction and dilation in rat middle cerebral arteries. J. Cereb. Blood Flow Metab. 21 (2001) 77-84
56. Zukowska-Grojec Z., Karwatowska-Prokopczuk E., Riose W., Rone J., Movafagh S., Ji H., Yeh Y., Chen W.T., Kleiman H.K., Grouzmann E., and Grant D.S. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 83 (1998) 187-195